| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CAC; CACT |
| WB Predicted band size | 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC25A20 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC25A20抗体的参考文献示例(注：部分文献为假设性示例，仅供参考)：
1. **文献名称**: "Functional characterization of SLC25A20 mutations in carnitine-acylcarnitine translocase deficiency"
**作者**: Huizing M, Iacobazzi V, IJlst L, et al.
**摘要**: 该研究通过Western blot和免疫荧光技术，利用SLC25A20特异性抗体，揭示了患者中因基因突变导致的蛋白表达缺失，阐明了脂肪酸氧化代谢障碍的分子机制。
2. **文献名称**: "Development and validation of a monoclonal antibody for the detection of SLC25A20 in human tissues"
**作者**: Smith J, Lee K, Patel R.
**摘要**: 研究团队开发了一种高特异性SLC25A20单克隆抗体，并通过免疫组化和流式细胞术验证其在多种组织样本中的应用，为代谢疾病的诊断提供了新工具。
3. **文献名称**: "Altered expression of SLC25A20 in hepatocellular carcinoma correlates with mitochondrial dysfunction"
**作者**: Zhang Y, Wang H, Chen X.
**摘要**: 通过免疫组化和Western blot分析，使用SLC25A20抗体发现肝癌组织中该蛋白表达显著下调，提示其可能通过影响线粒体功能参与肿瘤进展。
4. **文献名称**: "Carnitine-acylcarnitine translocase deficiency: Biochemical and molecular insights from patient-derived fibroblasts"
**作者**: Rubio-Gozalbo ME, Wanders RJ, Waterham HR.
**摘要**: 研究利用SLC25A20抗体对患者成纤维细胞进行蛋白表达分析，结合基因测序，明确了突变对肉碱转运功能的影响及临床表型关联。
**注**：以上文献标题和摘要内容为示例性质，具体文献需通过学术数据库(如PubMed、Google Scholar)检索确认。实际研究中，SLC25A20抗体的应用多集中于代谢疾病机制及诊断领域。
SLC25A20. also known as carnitine-acylcarnitine translocase (CACT), is a mitochondrial membrane protein belonging to the solute carrier family 25 (SLC25). It plays a critical role in fatty acid β-oxidation by facilitating the transport of acylcarnitines across the inner mitochondrial membrane, enabling their entry into the mitochondrial matrix for energy production. SLC25A20 deficiency is linked to rare autosomal recessive metabolic disorders characterized by impaired fatty acid oxidation, leading to life-threatening symptoms such as hypoglycemia, cardiomyopathy, and muscle weakness.
Antibodies targeting SLC25A20 are essential tools for studying its expression, localization, and function in cellular and disease contexts. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels in tissues or cell lines. Researchers employ SLC25A20 antibodies to investigate metabolic pathways, diagnose genetic disorders, or explore therapeutic strategies for conditions involving fatty acid metabolism defects. Specific validation of these antibodies—through knockout controls or siRNA silencing—is crucial to ensure specificity, given the structural similarities among mitochondrial carrier family proteins. Commercial SLC25A20 antibodies are typically raised against peptide sequences unique to the protein, often within its cytoplasmic or transmembrane domains. Understanding SLC25A20's role and its antibody applications advances research into mitochondrial biology and metabolic diseases.
×
